Key facts
- CroiValve’s last known valuation is $42.0M (Aug 2024).
- It has raised $43.0M; the latest was Later Stage VC ($2.9M) in Dec 2025.
- Notable investors include Enterprise Ireland, European Innovation Council, SOSV, MedTech Innovator, Elkstone — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for CroiValve
- ·The full record, as it builds
Funding rounds
No funding rounds for CroiValve are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CroiValve
Developer of a minimally invasive surgical device designed to treat severe tricuspid regurgitation. The company's device can be delivered through a vein and into the right heart, restoring the function of the tricuspid valve by sealing the central gap between the native valve leaflets, preventing regurgitation, enabling healthcare professionals to cost-effectively treat the patient's condition swiftly.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2016
- Employees
- 48
- Website
- croivalve.com/
- Ownership
- Privately Held (backing)
CroiValve doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CroiValve shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CroiValve in its N-PORT filings yet. We sweep new filings monthly.